Renal Cell Carcinoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Renal Cell Carcinoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month5 studies across 3 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | 2026-08-31 | in 11 d | 2024-11-19 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
January 2027 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCNCT07000149Number of participants with adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Active, not recruiting | 2027-01-29 | in 162 d | 2026-08-03 |
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
| KURA | Kura Oncology, Inc. | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Renal Cell Carcinoma
most recently updated first255 studies match. Showing the first 100 of 255 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| EXEL | Exelixis | $13.2B | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Enrolling by invitation | Drug: Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer | 5,000 | 2026-07-30 | 2030-05-31 | in 1,380 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| NXTC | NextCure, Inc. | $30M | A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552dose escalation: Dose-limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: SIM0505 for injection, SIM0505 for injection | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer | 738 | 2025-02-26 | Feb 2028 | ≤ 558 d | 2026-08-17 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)NCT07195682Number of Participants With Adverse Events (AEs) | Phase 1 | Recruiting | Drug: BMS-986506, Pumitamig, Ipilimumab | Renal Cell Carcinoma | 281 | 2026-01-15 | 2030-05-03 | in 1,352 d | 2026-08-11 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaNCT07594106Occurrence of Dose Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | 2026-07-20 | 2030-10-27 | in 1,529 d | 2026-08-05 |
| NTRA | Natera, Inc. | $44.9B | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization. | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC, Melanoma (Skin Cancer), Melanoma (Skin) Stage IV, CRC, MSI High Colorectal Cancer, DMMR Colorectal Cancer, RCC, Renal Cell Cancer, RCC, Solid Tumors, Metastatic Solid Tumors, Advanced Solid Tumors, Advanced Solid Tumors Cancer | 920 | Dec 2026 | Dec 2033 | ≤ 2,690 d | 2026-08-04 |
| XNCR | Xencor, Inc. | $1.9B | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaNCT05433142Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819) | Phase 1 | Recruiting | Biological: XmAb819 | Clear Cell Renal Cell Carcinoma | 307 | 2022-06-13 | Feb 2027 | ≤ 192 d | 2026-08-03 |
| AZN | AstraZeneca | — | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCNCT07000149Number of participants with adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Active, not recruiting | Drug: Volrustomig, Casdatifan | Advanced Clear Cell Renal Cell Carcinoma | 9 | 2025-07-28 | 2027-01-29 | in 162 d | 2026-08-03 |
| IPN.PA | Ipsen | $15.5B | Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsNCT03945773results2024-12-19Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review | Phase 2 | Completed | Drug: Cabozantinib | Locally Advanced or Metastatic Renal Cell Carcinoma | 127 | 2020-01-08 | 2023-05-11actual | — | 2026-07-31 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 | Phase 3 | Recruiting | Drug: Casdatifan, Cabozantinib, Placebo | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | 720 | 2025-09-08 | Apr 2028 | ≤ 619 d | 2026-07-31 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 Study of the Safety and Tolerability of CTX-10726NCT07419841Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses | Phase 1 | Recruiting | Drug: CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | 2026-05-28 | 2028-04-01 | in 590 d | 2026-07-31 |
| IPN.PA | Ipsen | $15.5B | Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.NCT03647878observationalThe proportion of subjects with dose reduction of cabozantinib due to Serious Adverse Events/Adverse Events (SAEs/AEs) | — | Active, not recruiting | — | Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 224 | 2018-09-24 | 2027-09-30 | in 406 d | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)NCT04106349observationalTreatment line | — | Active, not recruiting | — | Advanced or Metastatic Renal Cell Carcinoma | 150 | 2020-03-03 | 2027-03-31 | in 223 d | 2026-07-30 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsNCT05536141Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: casdatifan, Cabozantinib, Zimberelimab, Ipilimumab | Clear Cell Renal Cell Carcinoma, Solid Tumors | 362 | 2022-10-26 | Mar 2029 | ≤ 954 d | 2026-07-29 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| CHRS | Coherus Oncology, Inc. | $207M | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsNCT04374877[Part A] Dose Limiting Toxicity (DLT) | Phase 1 | Completed | Drug: CHS-388, Pembrolizumab, Toripalimab | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 145 | 2020-04-22 | 2025-05-28actual | — | 2026-07-15 |
| AZN | AstraZeneca | — | Savolitinib vs. Sunitinib in MET-driven PRCC.NCT03091192results2020-07-10Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) | Phase 3 | Active, not recruiting | Drug: Savolitinib, Sunitinib | Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors | 60 | 2017-07-25 | 2019-08-18actual | — | 2026-07-14 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: REGN5678, Cemiplimab | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 345 | 2019-08-12 | 2027-11-15 | in 452 d | 2026-07-09 |
| NVCT | Nuvectis Pharma, Inc. | $681M | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686Number of patients with treatment related adverse events and/or clinical laboratory abnormalities | Phase 1 | Recruiting | Drug: NXP900 | Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma | 140 | 2023-10-26 | Mar 2027 | ≤ 223 d | 2026-07-09 |
| AZN | AstraZeneca | — | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | Drug: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma | 13 | 2024-07-31 | 2026-12-31 | in 133 d | 2026-07-07 |
| PFE | Pfizer | $155.3B | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerNCT07227415Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator | Phase 1/2 | Recruiting | Drug: PF-08634404, Ipilimumab, Axitinib | Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma | 224 | 2026-02-10 | 2027-11-02 | in 439 d | 2026-07-06 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| BMY | Bristol-Myers Squibb | $134.9B | Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerNCT03455452observationalOverall Survival (OS) | — | Completed | — | Renal Cell Carcinoma, Renal Cell Cancer, Adenocarcinoma Of Kidney, Adenocarcinoma, Renal Cell, Kidney Cancer, Cancer of the Kidney | 623 | 2018-01-21 | 2025-12-18actual | — | 2026-06-16 |
| PFE | Pfizer | $155.3B | A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).NCT05858749observationalDemographical characteristics | — | Completed | — | Metastatic Renal Cell Carcinoma | 494 | 2022-06-20 | 2022-11-30actual | — | 2026-06-15 |
| KURA | Kura Oncology, Inc. | $1.1B | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: Darlifarnib, Cabozantinib, Adagrasib | Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC) | 300 | 2023-10-18 | Jan 2027 | ≤ 164 d | 2026-06-08 |
| IPN.PA | Ipsen | $15.5B | A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in AdultsNCT05361434observationalOverall survival (OS) rate (death of any cause) from the start of cabozantinib in combination with nivolumab. | — | Completed | — | Advanced Renal Cell Carcinoma | 311 | 2022-09-26 | 2025-10-20actual | — | 2026-06-01 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2023-04-19 | 2026-07-31 | — | 2026-06-01 |
| AZN | AstraZeneca | — | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)NCT00600496Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies. | Phase 1 | Completed | Drug: AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus | Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer | 140 | 2007-12-14 | 2010-08-20actual | — | 2026-05-27 |
| BMY | Bristol-Myers Squibb | $134.9B | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)NCT02231749results2018-10-16Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1 | Phase 3 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Sunitinib | Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 1,096 | 2014-10-16 | 2017-06-26actual | — | 2026-05-27 |
| INCY | Incyte Corporation | $24.7B | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)NCT03260894results2019-09-10Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC) | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib | Renal Cell Carcinoma (RCC) | 129 | 2017-12-07 | 2018-08-22actual | — | 2026-05-22 |
| AZN | AstraZeneca | — | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCNCT05043090Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib | Phase 3 | Active, not recruiting | Drug: savolitinib, durvalumab, sunitinib | Papillary Renal Cell Carcinoma | 148 | 2021-10-28 | 2025-12-31actual | — | 2026-05-22 |
| TIL | Instil Bio | $50M | ITIL-306 in Advanced Solid TumorsNCT05397093Frequency and severity of ITIL-306 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest (AESI) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated early due to discontinuation of development of the investigational program | Biological: ITIL-306 | Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma | 1 | 2022-08-24 | 2023-10-10actual | — | 2026-04-15 |
| ACTU | Actuate Therapeutics Inc. | $25M | 9-ING-41 in Patients With Advanced CancersNCT03678883Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 2 | Active, not recruiting | Drug: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 350 | 2019-01-04 | Jun 2026 | — | 2026-04-03 |
| PFE | Pfizer | $155.3B | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerNCT06580938Number of Participants With Dose-Limiting Toxicity (DLT) (Parts 1 and 2) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Biological: PF-07921585, Sasanlimab | Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer | 4 | 2024-11-11 | 2025-07-14actual | — | 2026-03-23 |
| PFE | Pfizer | $155.3B | Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life SettingNCT02184416observationalProgression-Free Survival (PFS) | — | Completed | Other: observational | Metastatic Renal Cell Carcinoma (mRCC) | 554 | 2014-10-31 | 2022-09-30actual | — | 2026-02-27 |
| 4523.T | Eisai Inc. | $8.7B | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaNCT02811861results2021-09-24Progression-free Survival (PFS) by Independent Imaging Review (IIR) | Phase 3 | Active, not recruiting | Drug: Lenvatinib, Everolimus, Pembrolizumab, Sunitinib | Renal Cell Carcinoma | 1,069 | 2016-10-13 | 2020-08-28actual | — | 2026-02-23 |
| PFE | Pfizer | $155.3B | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.NCT06546553PART 1: Number of participants with Dose-limiting toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations and not based on safety concerns. | Drug: PF-07826390 · Biological: sasanlimab · Other: SOC (anti-PD-1 + platinum -based chemo) | Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 10 | 2024-09-06 | 2025-10-03actual | — | 2026-02-23 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerNCT03873402Progression free survival (PFS) by blinded independent central review (BICR) | Phase 3 | Active, not recruiting | Biological: Nivolumab, Ipilimumab · Other: Ipilimumab placebo | Renal Cell Carcinoma | 437 | 2019-06-21 | 2027-03-11 | in 203 d | 2026-01-21 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive CancerNCT06840548Cohort A: Dosimetry - Effective dose equivalent (mSv) | Phase 1 | Completed | Drug: [68Ga]Ga-OncoCAIX | Clear Cell Renal Cell Carcinoma (ccRCC) | 20 | 2025-04-16 | 2025-11-28actual | — | 2026-01-13 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsNCT05795595Phase 1 (Dose Escalation): Incidence of adverse events | Phase 1/2 | Completed | Biological: CTX131 | Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma | 19 | 2023-03-13 | 2025-09-18actual | — | 2025-11-26 |
| AZN | AstraZeneca | — | Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCCNCT07024680observationalThe primary objective is to characterize the real-world PFS (rwPFS) with either sunitinib or sorafenib. | — | Recruiting | Other: Observational, None intervention | Papillary Renal Cell Carcinoma | 150 | 2025-03-31 | 2026-07-14 | — | 2025-11-18 |
| BOLT | Bolt Biotherapeutics, Inc. | $6M | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesNCT06052852Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to CTCAE v5.0 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BDC-3042, Cemiplimab | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma | 17 | 2023-10-11 | 2025-08-01actual | — | 2025-11-17 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsNCT06345183observationalParticipant year of birth | — | Completed | Combination product: Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy | Advanced Renal Cell Carcinoma (aRCC) | 327 | 2024-02-19 | 2024-04-04actual | — | 2025-11-06 |
| NANO.PA | Nanobiotix | — | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyNCT03589339[Dose Escalation Part]: Determination of the Recommended Dose | Phase 1 | Active, not recruiting | Drug: NBTXR3, Nivolumab, Pembrolizumab · Radiation: SABR | Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder) | 145 | 2019-01-16 | 2027-04-30 | in 253 d | 2025-10-24 |
| MGNX | MacroGenics | $261M | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496Number of participants with adverse events (AEs) | Phase 1 | Completed | Biological: vobramitamab duocarmazine, lorigerlimab | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma | 31 | 2022-04-19 | 2025-06-24actual | — | 2025-10-14 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT04169711Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment | Phase 1 | Completed | Drug: ARO-HIF2 | Clear Cell Renal Cell Carcinoma | 26 | 2020-08-17 | 2022-01-24actual | — | 2025-10-09 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadNCT04810078Time-averaged serum concentration over 28 days (Cavgd28) | Phase 3 | Active, not recruiting | Biological: Nivolumab and rHuPH20, Nivolumab | Clear Cell Renal Cell Carcinoma | 681 | 2021-05-21 | 2025-07-29actual | — | 2025-10-09 |
| PFE | Pfizer | $155.3B | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsNCT06285097Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07820435 · Biological: Sasanlimab | Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 9 | 2024-02-08 | 2025-01-03actual | — | 2025-09-17 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219results2025-09-10Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC) | Phase 3 | Active, not recruiting | Drug: Cabozantinib, Cabozantinib-matched placebo · Biological: Nivolumab, Ipilimumab | Renal Cell Carcinoma | 855 | 2019-06-25 | 2022-01-31actual | — | 2025-09-10 |
| GH | Guardant Health, Inc. | $21.5B | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | 2021-09-07 | Aug 2029 | ≤ 1,107 d | 2025-08-22 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| INCY | Incyte Corporation | $24.7B | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914results2021-09-30Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1 | Completed | Drug: INCB001158, Pembrolizumab | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | 260 | 2016-09-14 | 2020-04-30actual | — | 2025-08-05 |
| PFE | Pfizer | $155.3B | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)NCT02684006results2024-10-29Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants | Phase 3 | Completed | Drug: Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib | Renal Cell Cancer | 886 | 2016-03-23 | 2023-08-31actual | — | 2025-07-30 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsNCT04707248Number of Participants With Dose-limiting toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: DS-6000a, DS-6000a | Renal Cell Carcinoma, Ovarian Tumor | 179 | 2020-12-22 | 2026-04-30 | — | 2025-07-28 |
| PFE | Pfizer | $155.3B | Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine PracticeNCT02533258results2017-10-05observationalDuration of Axitinib Treatment | — | Completed | — | Renal Cell Carcinoma | 13 | 2015-12-02 | 2016-05-12actual | — | 2025-07-16 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyNCT02940639observationalOverall Survival (OS) | — | Completed | — | Renal Cell Carcinoma | 499 | 2016-10-27 | 2025-06-03actual | — | 2025-07-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaNCT04513522results2025-07-11Total Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE) | Phase 4 | Completed | Biological: Nivolumab, Ipilimumab | Kidney Neoplasms | 101 | 2020-12-17 | 2024-01-04actual | — | 2025-07-11 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| ISRG | Intuitive Surgical | $138.2B | Open vs Robotic Assisted Partial NephrectomyNCT0384982030 day complications | Not applicable | Terminatedsponsor's stated reason: Due to low enrollment the study was terminated | Device: Robotic-assisted partial nephrectomy · Other: Open partial nephrectomy | Renal Cancer | 247 | 2019-03-12 | 2021-12-15actual | — | 2025-06-17 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03141177results2022-04-26Progression Free Survival (PFS) | Phase 3 | Active, not recruiting | Biological: Nivolumab, Ipilimumab · Drug: Cabozantinib, Sunitinib | Renal Cell Carcinoma | 701 | 2017-07-23 | 2020-02-12actual | — | 2025-06-06 |
| PFE | Pfizer | $155.3B | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2019-11-13 | 2024-12-10actual | — | 2025-05-28 |
| STTK | Shattuck Labs, Inc. | $748M | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618results2025-03-14Safety Profile of SL-279252 | Phase 1 | Completed | Drug: SL-279252 | Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2019-03-26 | 2023-05-04actual | — | 2025-04-02 |
| 4523.T | Eisai Inc. | $8.7B | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaNCT03173560results2021-03-05Objective Response Rate at Week 24 (ORR24W) | Phase 2 | Completed | Drug: lenvatinib, everolimus | Renal Cell Carcinoma | 343 | 2017-08-17 | 2020-02-14actual | — | 2025-04-01 |
| INCY | Incyte Corporation | $24.7B | Study of INCB086550 in Select Solid TumorsNCT04629339results2025-03-13Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile. | Drug: INCB086550 | Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Melanoma | 16 | 2021-09-02 | 2024-03-26actual | — | 2025-03-13 |
| INCY | Incyte Corporation | $24.7B | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsNCT05909995Occurence of DLTs | Phase 1 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCB 99280 with Ipilimumab | Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC) | 8 | 2023-08-29 | 2024-09-19actual | — | 2025-02-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in JapanNCT04043975observationalObjective Response Rate (ORR) | — | Completed | — | Advanced or Metastatic Renal Cell Carcinoma | 286 | 2019-09-19 | 2024-08-23actual | — | 2025-02-14 |
| PFE | Pfizer | $155.3B | Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).NCT05534789results2025-01-20observationalProgression Free Survival (PFS) | — | Terminatedsponsor's stated reason: The trial prematurely terminated due to the inability to recruit the planned number of participants. The decision to terminate the trial was not based on any safety and/or efficacy concerns. | — | Carcinoma, Renal Cell | 106 | 2022-10-15 | 2023-12-13actual | — | 2025-01-20 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)NCT04438083Part A (dose escalation): Incidence of adverse events | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX130 | Renal Cell Carcinoma | 19 | 2020-06-16 | 2024-10-08actual | — | 2025-01-08 |
| PFE | Pfizer | $155.3B | To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell CarcinomaNCT04682587results2025-01-03observationalNumber of Participants With Different Type of Adverse Events | — | Completed | Drug: Axitinib, Avelumab, Pembrolizumab | Renal Cell Carcinoma | 481 | 2021-02-24 | 2021-04-05actual | — | 2025-01-03 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyNCT03138512results2024-12-18Disease-Free Survival (DFS) by BICR - Treatment Part A and B | Phase 3 | Completed | Biological: nivolumab, ipilimumab · Drug: nivolumab placebo, ipilimumab placebo | Carcinoma, Renal Cell | 1,641 | 2017-07-07 | 2023-09-28actual | — | 2024-12-18 |
| IPN.PA | Ipsen | $15.5B | Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationNCT04957160observationalDescription of the treatment sequence pathway from 1L up to 2L for patients with aRCC | — | Completed | — | Advanced Renal Cell Carcinoma (aRCC) | 281 | 2021-09-09 | 2022-06-15actual | — | 2024-12-17 |
| EXEL | Exelixis | $13.2B | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | Drug: XL092, Atezolizumab, Avelumab | Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer | 325 | 2019-03-20 | 2026-08-31 | in 11 d | 2024-11-19 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerNCT03809624Frequency of adverse events of INBRX-105 | Phase 1 | Terminatedsponsor's stated reason: Program terminated due to lack of meaningful efficacy signal. | Drug: INBRX-105 - PDL1x41BB antibody, Pembrolizumab | Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma | 160 | 2019-01-30 | 2024-10-03actual | — | 2024-10-23 |
| XFOR | X4 Pharmaceuticals | $417M | Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaNCT02667886results2024-08-14Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Completed | Drug: X4P-001, axitinib | Clear Cell Renal Cell Carcinoma | 74 | 2016-04-27 | 2022-04-14actual | — | 2024-10-03 |
| PFE | Pfizer | $155.3B | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.NCT05363072results2024-10-01observationalNumber of Participants According to Co-Diagnoses Before Index | — | Completed | — | Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney, Kidney Cancer, Kidney Neoplasms, Renal Cancer | 1,112 | 2022-05-02 | 2022-06-08actual | — | 2024-10-01 |
| PFE | Pfizer | $155.3B | Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)NCT01210482results2024-09-25observationalNumber of Participants With Adverse Drug Reactions | — | Completed | Drug: Temsirolimus | Renal Cell Carcinoma | 1,050 | 2010-08-24 | 2018-03-30actual | — | 2024-09-25 |
| PFE | Pfizer | $155.3B | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]NCT00700258results2024-09-23observationalOverall Survival (OS) | — | Completed | Drug: Temsirolimus, Temsirolimus, Sunitinib, Sunitinib, Axitinib | Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors | 1,520 | 2008-02-13 | 2021-12-28actual | — | 2024-09-23 |
| PFE | Pfizer | $155.3B | Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCCNCT04375150results2024-09-19observationalNumber of Participants With First Line Treatment Regimen | — | Completed | Drug: Tyrosine kinase inhibitor (TKI), Immuno-oncology (IO) | Renal Cell Carcinoma (RCC) | 355 | 2019-12-02 | 2022-10-28actual | — | 2024-09-19 |
| AZN | AstraZeneca | — | A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.NCT00378482results2021-05-28Safety Endpoints: Serious Adverse Events to Tremelimumab. | Phase 2 | Completed | Drug: CP-675,206 (Tremelimumab) | Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms, Patients Who Have/Have Had Melanoma and Other Tumors | 37 | 2007-03-05 | 2023-10-27actual | — | 2024-08-22 |
| PFE | Pfizer | $155.3B | A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.NCT05745142results2024-08-05observationalObjective Response Rate (ORR) According to Disease Risk Group in IMDC | — | Completed | Drug: Sunitinib | Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma | 376 | 2023-02-23 | 2023-02-23actual | — | 2024-08-05 |
| PFE | Pfizer | $155.3B | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsNCT04628780results2024-07-29Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations | Biological: PF-07209960 | Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 37 | 2020-12-16 | 2023-05-03actual | — | 2024-07-29 |
| PFE | Pfizer | $155.3B | Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National RegistriesNCT04669366results2024-07-19observationalNumber of Participants With at Least 1 Filled Sunitinib Prescription | — | Completed | Drug: sunitinib, axitinib | Kidney Neoplasms | 1,205 | 2021-01-20 | 2021-07-31actual | — | 2024-07-19 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| PFE | Pfizer | $155.3B | PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsNCT03685591results2024-06-26Number of Participants With First-Cycle Dose-Limiting Toxicitys (DLTs) by Treatment | Phase 1 | Terminatedsponsor's stated reason: The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority. | Drug: PF-06952229, Enzalutamide | Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms | 49 | 2018-10-04 | 2022-03-30actual | — | 2024-06-26 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-301 in Patients With Selected Advanced Solid TumorsNCT03621982results2024-06-13Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study. | Drug: ADCT-301 · Biological: Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 78 | 2018-11-09 | 2022-12-14actual | — | 2024-06-13 |
| IPN.PA | Ipsen | $15.5B | Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsNCT03776123observationalNumber of patients experiencing Adverse Events (AEs)/ Serious Adverse Events (SAEs) after Cabometyx™ administration | — | Completed | — | Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma | 347 | 2019-05-15 | 2024-03-26actual | — | 2024-05-29 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesNCT03629756Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: Etrumadenant, Zimberelimab | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer | 48 | 2018-07-24 | 2021-08-18actual | — | 2024-05-24 |
| PFE | Pfizer | $155.3B | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.NCT03140176results2024-05-10observationalProgression Free Survival (PFS) | — | Terminatedsponsor's stated reason: The study was terminated early due to the inability to recruit the planned number of patients | Drug: Sunitinib | Metastatic Renal Cell Carcinoma | 77 | 2017-08-15 | 2022-01-22actual | — | 2024-05-10 |
| PFE | Pfizer | $155.3B | Study of PF-07263689 in Participants With Selected Advanced Solid TumorsNCT05061537results2024-04-12Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study. | Biological: PF-07263689, Sasanlimab | Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma | 13 | 2021-10-20 | 2022-10-14actual | — | 2024-04-12 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| PFE | Pfizer | $155.3B | Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South KoreaNCT02156895results2024-03-08observationalNumber of Participants With Adverse Events (AEs), Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) | — | Completed | Drug: Axitinib | Advanced Renal Cell Carcinoma | 111 | 2018-07-17 | 2021-04-21actual | — | 2024-03-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Renal Cell Carcinoma is matched — 28 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Renal Cell Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Metastatic Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Renal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Cell Cancer
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Clear-cell Metastatic Renal Cell Carcinoma
- Advanced or Metastatic Renal Cell Carcinoma
- Metastatic Renal Cell Cancer
- Papillary Renal Cell Carcinoma
- Adenocarcinoma, Renal Cell
- Advanced Clear Cell Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma (aRCC)
- Carcinoma, Renal Cell Metastasis
- Carcinoma, Renal Cell, Advanced
- Locally Advanced or Metastatic Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma ( mRCC)
- Metastatic Renal Cell Carcinoma (mRCC)
- Metastatic/Advanced Renal Cell Carcinoma
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- RCC
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Renal Cell Carcinoma” (a text search, wider than this page)